Relevance of clinical trial results in myocardial infarction to medical practice: Comparison of four year outcome in participants of a thrombolytic trial, patients receiving routine thrombolysis, and those deemed ineligible for thrombolysis

Heart

Volumn 81, Issue 6, 1999, Pages 598-602

  Brown, N ^a   Melville, M ^a   Gray, D ^a   Young, T ^b   Skene, A M ^b   Wilcox, R G ^a   Hampton, J R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Clinical trials; Myocardial infarction; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; DISEASE CLASSIFICATION; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; OUTCOMES RESEARCH; PATIENT CODING; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0032973767     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.81.6.598     Document Type: Article

References (24)

1. Appleby P, Baigent C, Collins R, et al. Indications for fibri nolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
2. The LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
4. Brown N, Young T, Gray D, et al. Inpatient deaths from acute myocardial infarction, 1982-92: analysis of data in the Nottingham heart attack register. BMJ 1997;315:159-64.
5. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996;312:1637-41.
6. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1988;2:525-30.
7. Ozbek C, Heisel A, Krause M, et al. Comparison of mortality from acute myocardial infarction in patients receiving anistreplase with those not receiving thrombolysis. Am J Cardiol 1995;76:1103-7.
8. Jha P, Deboer D, Sykora K, et al. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 1996;27:1335-42.
9. Gray D, Keating NA, Murdock J, et al. Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction. Lancet 1993;341:654-7.
10. Rose GA. Cardiovascular survey methods, 2nd ed. Geneva: World Health Organization, 1982.
11. Cox DR, Oaks D. Analysis of survival data. London: Chapman and Hall, 1984.
12. S-plus guide to statistical and mathematical analysis, version 3.2. Seattle: Statistical Sciences, 1993.
13. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
14. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
15. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31.
16. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-402.
17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
18. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669-77.
19. Behar S, Gottlieb S, Hod H, et al. The outcome of patients with acute myocardial infarction ineligible for thrombolytic therapy. Israeli thrombolytic survey group. Am J Med 1996;101:184-91.
20. Himbert D, Juliard JM, Steg PG, et al. Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis. Am J Cardiol 1993;71:377-81.
21. Boyle RM. Immediate angioplasty in the United Kingdom. Br Heart J 1995;73:413-14.
22. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med 1996;335:1880-7.
23. Nash IS, Nash DB, Fuster V. Do cardiologists do it better? J Am Cardiol 1997;29:175-8.
24. Pilote L, Miller DP, Califf RM, et al. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996;335:1198-205.